The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Abstract
The second generation BCR/ABL kinase inhibitor nilotinib is increasingly used for the treatment of imatinib‐resistant chronic myeloid leukemia (CML). So far, nilotinib is considered a well‐tolerated drug with little if any side effects, although an increase in the fasting glucose level has been reported. We examined a series of 24 consecutive CML patients treated with nilotinib in our center for the development of non‐hematologic adverse events. Three of these 24 CML patients developed a rapidly progressive peripheral arterial occlusive disease (PAOD) during treatment with nilotinib. In all three cases, PAOD required repeated angioplasty and/or multiple surgeries within a few months. No PAOD was known before nilotinib‐therapy in these patients, although all three had received imatinib. In two patients, pre‐existing risk factors predisposing for PAOD were known, and one of them had developed diabetes mellitus during nilotinib. In the other 21 patients treated with nilotinib in our center, one less severe PAOD, one myocardial infarction, one spinal infarction, one subdural hematoma, and one sudden death of unknown etiology were recorded. In summary, treatment with nilotinib may be associated with an increased risk of vascular adverse events, including PAOD development. In a subgroup of patients, these events are severe or even life‐threatening. Although the exact mechanisms remain unknown, we recommend screening for pre‐existing PAOD and for vascular risk factors such as diabetes mellitus in all patients before starting nilotinib and in the follow up during nilotinib‐therapy. Am. J. Hematol. 2011. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationChronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Branford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D.-W., Radich, J. P., Saglio, G., Pane, F., Kamel-Reid, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-150680 · Cited by 388
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P. W., Buchdunger, E., Walker, C., & Jarai, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.014 · Cited by 277
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Manley, P. W., Drueckes, P., Fendrich, G., Furet, P., Liebetanz, J., Martiny-Baron, G., Mestan, J., Trappe, J., Wartmann, M., & Fabbro, D. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.008 · Cited by 225
How I treat chronic myeloid leukemia in the imatinib era
Goldman, J. M. (2007) · Blood · doi:10.1182/blood-2007-04-038943 · Cited by 212
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Rosti, G., Palandri, F., Castagnetti, F., Breccia, M., Levato, L., Gugliotta, G., Capucci, A., Cedrone, M., Fava, C., Intermesoli, T., et al. (2009) · Blood · doi:10.1182/blood-2009-07-232595 · Cited by 210
Molecular mechanisms of transformation by the BCR-ABL oncogene
Sattlermc, M., & Griffin, J. D. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70013-4 · Cited by 203
Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling
Ferri, N., Carragher, N. O., & Raines, E. W. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63716-9 · Cited by 173
Large and Small Vessels Atherosclerosis: Similarities and Differences
Aboyans, V., Lacroix, P., & Criqui, M. H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.04.001 · Cited by 146
Imatinib Attenuates Diabetes-Associated Atherosclerosis
Lassila, M., Allen, T. J., Cao, Z., Thallas, V., Jandeleit-Dahm, K. A. M., Candido, R., & Cooper, M. E. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000124105.39900.db · Cited by 142
Franco, C. D., Hou, G., Ahmad, P. J., Fu, E. Y. K., Koh, L., Vogel, W. F., & Bendeck, M. P. (2008) · Circulation Research · doi:10.1161/circresaha.107.170662 · Cited by 125
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
Druker, B. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206081 · Cited by 116
The riddle of the mast cell: kit(CD117)-ligand as the missing link?
Valent, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90153-8 · Cited by 112
Self-citationBreccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F., & Alimena, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.217 · Cited by 106
The Mast Cell as Site of Tissue-Type Plasminogen Activator Expression and Fibrinolysis
Sillaber, C., Baghestanian, M., Bevec, D., Willheim, M., Agis, H., Kapiotis, S., Füreder, W., Bankl, H. C., Kiener, H. P., Speiser, W., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.1032 · Cited by 104
Self-citationFranco, C. D., Britto, K. E., Wong, E., Hou, G., Zhu, S.-N., Chen, M., Cybulsky, M. I., & Bendeck, M. P. (2009) · Circulation Research · doi:10.1161/circresaha.109.207357 · Cited by 93
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli, G., Soverini, S., Rosti, G., Cilloni, D., & Baccarani, M. (2005) · PubMed · Cited by 70
Franco, C. D., Ahmad, P. J., Hou, G., Wong, E., & Bendeck, M. P. (2010) · Circulation Research · doi:10.1161/circresaha.109.213637 · Cited by 67
Valent, P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07197.x · Cited by 66
Self-citationBreccia, M., Muscaritoli, M., Gentilini, F., Latagliata, R., Carmosino, I., Fanelli, F. R., & Alimena, G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.01.024 · Cited by 65
Optimizing therapy of chronic myeloid leukemia
Deininger, M. W. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.023 · Cited by 45
Regulation of Development, Survival and Neoplastic Growth of Mast Cells through the c-kit Receptor
Kitamura, Y., Tsujimura, T., Jippo, T., Kasugai, T., & Kanakura, Y. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000236929 · Cited by 31
Nilotinib: A Phenylamino-Pyrimidine Derivative with Activity Against BCR-ABL, KIT and PDGFR Kinases
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Future Oncology · doi:10.2217/14796694.4.5.611 · Cited by 25
New Directions in the Treatment of Imatinib Failure and/or Resistance
Giles, F. J. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.01.011 · Cited by 15
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Kroschinsky, F., Stölzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., & Schellongowski, P. (2017) · Critical Care · doi:10.1186/s13054-017-1678-1 · Cited by 500
Metadata
- Authors
- Aichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2011-04-27
- Volume
- 86
- Issue
- 7
- Pages
- 533-539
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2051566553
- Cited by
- 296
- References
- 35
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.